The 38-week and 52-week results are going to be heavily watched. If they are definitive (good or bad), it will have an effect on the company's market cap. If the results continue to be ambiguous, the share price will languish around current levels.
The MCI and the donepezil-naive stratifications are our greatest hope. (There may be some correlation between them but that can be addressed in a large Phase 2/3.)
News 
Market Data 
Discover 
AI
